Abercrombie & Fitch Co. (NYSE:ANF) maintained its Market Perform rating by William Blair, ahead of the company's earnings report scheduled for March 5. Dylan Carden, representing the research firm, ...

William Blair reaffirmed their positive stance on Birkenstock Holding plc (NYSE:BIRK), maintaining an Outperform rating on the company's shares. The firm's analysts highlighted Birkenstock's robust ...

Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for AZEK in a research note issued on ...

William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. William ...

William Blair downgraded Sprinklr (CXM) to Market Perform from Outperform without a price target after the company announced a 15% global ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

William Blair last night initiated coverage of Rubrik (RBRK) with a Market Perform rating. While Rubrik’s growth runway “ooks long and its competitive moat durable,” the stock’s risk ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.